Dec 30, 2025 • MarketBeat
SOMEWHAT-BEARISH
Louise Frederika Kooij Sells 75,117 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) Stock
Louise Frederika Kooij, CAO of NewAmsterdam Pharma (NASDAQ:NAMS), sold 75,117 shares on December 23rd at $36.21, totaling over $2.7 million. This sale reduced her ownership by 83.35% to 15,000 shares, following other significant sales in late December. The company's stock has a "Moderate Buy" consensus from analysts with an average target price of $45.90, despite reporting negative EPS and net margins.
Dec 30, 2025 • MarketBeat
SOMEWHAT-BEARISH
NewAmsterdam Pharma (NASDAQ:NAMS) CAO Sells $928,072.48 in Stock
NewAmsterdam Pharma's CAO, Louise Frederika Kooij, sold 26,011 shares of the company's stock for $928,072.48 on December 24th, reducing her stake by 63.42%. This sale was part of a larger divestment totaling over $5 million across three transactions in December. The company's stock traded down 0.7% to $35.02, following a quarterly EPS miss and lower-than-expected revenue.
Dec 30, 2025 • MarketBeat
BEARISH
Insider Selling: NewAmsterdam Pharma (NASDAQ:NAMS) CAO Sells 43,872 Shares of Stock
NewAmsterdam Pharma's Chief Accounting Officer, Louise Frederika Kooij, sold 43,872 shares of NewAmsterdam Pharma stock on December 26th for $1.5 million, reducing her stake by 74.52%. These sales are part of a larger trend of over 145,000 shares sold in late December, totaling approximately $5.20 million. The company's stock trades down 0.7% at $35.02, possessing a market cap of $3.97 billion, and analysts currently have a "Moderate Buy" rating with an average price target of $45.90 despite recent earnings misses.
Dec 22, 2025 • Stock Traders Daily
NEUTRAL
(NAMS) Volatility Zones as Tactical Triggers
This article provides an analysis of Newamsterdam Pharma Company N.v. (NASDAQ: NAMS), highlighting weak near and mid-term sentiment that could impact its long-term positive outlook. It details various AI-generated trading strategies, including position trading, momentum breakout, and risk hedging, with specific entry zones, targets, and stop losses. The analysis also covers multi-timeframe signal analysis, showing weak signals in the near and mid-term but a strong signal for the long-term, supported by an exceptional risk-reward setup targeting a 22.2% gain.
Dec 16, 2025 • Stock Traders Daily
NEUTRAL
Understanding Momentum Shifts in (NAMSW)
This article analyzes momentum shifts for Newamsterdam Pharma Company N.v. Warrant (NASDAQ: NAMSW), highlighting a positive near-term sentiment within a long-term strong context, despite a mid-term weak bias. It details an exceptional risk-reward setup targeting a 26.5% gain and outlines three distinct AI-generated trading strategies for different risk profiles. The analysis also provides multi-timeframe signal analysis with support and resistance levels.
Dec 14, 2025 • MarketBeat
SOMEWHAT-BULLISH
Frazier Life Sciences Management L.P. Has $300.75 Million Stock Position in NewAmsterdam Pharma Company N.V. $NAMS
Frazier Life Sciences Management L.P. significantly increased its stake in NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) to $300.75 million, representing 14.79% ownership. Institutional investment in NewAmsterdam Pharma is high at nearly 90%, with multiple major funds adding to their positions. While the company missed recent EPS and revenue estimates, analysts maintain a "Moderate Buy" rating with an average target price of $45.30.